{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:16:40Z","timestamp":1777396600256,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:p>\u00a0The recent Alva et al. Phase 3b study on pimavanserin use in older adults with neurodegenerative diseases (NDDs), specifically including Alzheimer\u2019s disease, vascular dementia, Parkinson\u2019s disease (with or without dementia), frontotemporal dementia, and dementia with Lewy bodies, provides important new data on its safety for managing neuropsychiatric symptoms in this population. This commentary on the study further examines the findings within the broader context of antipsychotic therapy as it has evolved from chlorpromazine to pimavanserin in a continuous search for greater safety. Comparing pimavanserin\u2019s safety and efficacy profile with historical data and regulatory milestones provides a nuanced perspective for clinicians regarding the significance of the drug\u2019s known advantages over prior antipsychotic treatments. More research is needed to determine the full potential of pimavanserin to improve neuropsychiatric symptoms in older adults with NDDs.<\/jats:p>","DOI":"10.3233\/jad-240274","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:09:06Z","timestamp":1716289746000},"page":"1217-1220","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pimavanserin\u2019s Safety Profile: Insights from a Phase 3b Clinical Trial"],"prefix":"10.1177","volume":"99","author":[{"given":"Ismaeel","family":"Yunusa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-231167"},{"key":"ref002","unstructured":"MageeP (2021) How Thorazine Shows That Medical and Social Histories Shape Each Other. Out of the stacks, Staff research \u2013 #MedievalMedicineMonday. College of Physicians of Philadelphia. February 22, 2021. Accessed February 27, 2024. https:\/\/histmed.collegeofphysicians.org\/how-thorazine-shows\/"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316658463"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1360"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16r11119"},{"key":"#cr-split#-ref007.1","unstructured":"EllisB, HickenM (2024) FDA worried drug was risky"},{"key":"#cr-split#-ref007.2","unstructured":"now reports of deaths spark concern. CNN. April 9, 2018. Accessed February 27, 2024. https:\/\/www.cnn.com\/2018\/04\/09\/health\/parkinsons-drug-nuplazid-invs\/index.html"},{"key":"ref008","unstructured":"Institute for Safe Medication Practices (2024) Safety Signals for Two Novel Drugs. ISMP QuarterWatch: Monitoring FDA MedWatch Reports. November 1, 2017. Accessed February 27, 2024. https:\/\/www.ismp.org\/sites\/default\/files\/attachments\/2018-01\/2017Q1_0.pdf"},{"key":"ref009","unstructured":"U.S. Food and Drug Administration (2024) FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson\u2019s disease psychosis. September 20, 2018. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-analysis-finds-no-new-or-unexpected-safety-risks-associated-nuplazid-pimavanserin-medication. Accessed February 27, 2024."},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13652"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01260-6"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21090876"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.6.785"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.08.013"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012601"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.173501"},{"key":"ref017","unstructured":"Alzheimer Society of Canada (2024) Use of antipsychotic medications to treat people with dementia in long-term care homes: Position statement. June 7, 2017. Available at: https:\/\/alzheimer.ca\/sites\/default\/files\/documents\/ASC-statement_use-of-antipsychotic-medications.pdf. Accessed February 27, 2024."},{"key":"ref018","unstructured":"National Institute for Health and Care Excellence (2024) Dementia: Supporting people with dementia and their carers in health and social care. November 22, 2006. Accessed February 27, 2024. https:\/\/www.nice.org.uk\/guidance\/CG42"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610215000745"},{"key":"ref020","unstructured":"Best Practice Advocacy Centre New Zealand (BPACNZ) (2024) Managing patients with dementia: What is the role of antipsychotics? December 2013. Accessed February 27, 2024. https:\/\/bpac.org.nz\/bpj\/2013\/december\/dementia.aspx"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-240274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-240274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-240274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:47Z","timestamp":1777370927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-240274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6,11]]}},"alternative-id":["10.3233\/JAD-240274"],"URL":"https:\/\/doi.org\/10.3233\/jad-240274","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]}}}